Trials / Completed
CompletedNCT00048230
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 620 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2004-07-01
- Completion
- 2004-12-01
- First posted
- 2002-10-30
- Last updated
- 2012-01-13
Locations
93 sites across 13 countries: United States, Austria, Belgium, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00048230. Inclusion in this directory is not an endorsement.